EP Patent

EP1309564B1 — Arylethene-sulfonamides, their preparation and their use as endothelin antagonists

Assigned to Actelion Pharmaceuticals Ltd · Expires 2006-06-14 · 20y expired

What this patent protects

The invention relates to novel aryl-ethene sulfonamides of the general formula (I); wherein the symbols R1-R6, X, Y, Z and Q have the significance given in the description; and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also c…

USPTO Abstract

The invention relates to novel aryl-ethene sulfonamides of the general formula (I); wherein the symbols R1-R6, X, Y, Z and Q have the significance given in the description; and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Drugs covered by this patent

Patent Metadata

Patent number
EP1309564B1
Jurisdiction
EP
Classification
—
Expires
2006-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.